Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186808 | 0.85 | MCHR1 (0.56) | LMNAKDM4EPRKDCMCHR1KCNH2 | |
| SCHEMBL6186119 | 0.84 | LMNA (0.49) | LMNAKDM4ETSHRMCHR1KCNH2 | |
| SCHEMBL6187787 | 0.84 | MCHR1 (0.58) | LMNAKDM4EPRKDCMCHR1KMT2A | |
| Hydrochloric Acid SCHEMBL6315207 | 0.83 | MCHR1 (0.57) | LMNAKDM4EPRKDCMCHR1KMT2A | |
| SCHEMBL6187519 | 0.83 | LMNA (0.75) | LMNAKDM4EMCHR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL23360443 | 0.82 | LMNA (0.73) | LMNAKDM4EMCHR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL29862517 | 0.82 | LMNA (0.73) | LMNAKDM4EMCHR1HSD17B10 | |
| SCHEMBL6206875 | 0.81 | KDM4E (0.49) | LMNAKDM4EMCHR1KCNH2 | |
| SCHEMBL6189457 | 0.81 | LMNA (0.49) | LMNAKDM4EMCHR1BRD4ATAD2 | |
| SCHEMBL6313130 | 0.81 | PRKDC (0.62) | LMNAKDM4ETSHRPRKDCMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | LMNA 3781/4885KDM4E 1548/4885TSHR 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.